Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
PDGFR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

PDGFR

Chemical Structure Cat. No. Product Name CAS No.
Olaratumab Chemical Structure
BCP30495 Olaratumab 1024603-93-7
Olaratumab is a monoclonal antibody for the treatment of solid tumors.
Vorolanib Chemical Structure
BCP30430 Vorolanib 1013920-15-4
Vorolanib, also known as CM-082 and X-82, is small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities.
N-Desethyl Sunitinib Chemical Structure
BCP20914 N-Desethyl Sunitinib 356068-97-8
N-Desethyl Sunitinib is a metabolite of sunitinib.
JNJ-10198409 Chemical Structure
BCP08276 JNJ-10198409 627518-40-5
JNJ-10198409, also known as RWJ-540973, is an inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM.
SU 4312 Chemical Structure
BCP20743 SU 4312 5812-07-7
Potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). Selective over EGFR and c-Src tyrosine kinases.
DCC-2618 Chemical Structure
BCP29218 DCC-2618 1442472-39-0
DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.
SIM010603 Chemical Structure
BCP25213 SIM010603 1032265-67-0
SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor.
TG 100801 Hydrochloride Chemical Structure
BCP25254 TG 100801 Hydrochloride 1018069-81-2
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
Sitravatinib Chemical Structure
BCP29099 Sitravatinib 1123837-84-2
Sitravatinib (MGCD516,MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
ABT-348 Chemical Structure
BCP07256 ABT-348 1227939-82-3
ABT-348, is a novel potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases and is currently in Phase I clinical trials.
123下一页末页共 64 条记录 1 / 7 页 
0086-15971444841